Page last updated: 2024-12-11

tiaprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6441899
CHEMBL ID2104879
CHEBI ID180617
SCHEMBL ID867741
MeSH IDM0119270

Synonyms (26)

Synonym
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e)-3-hydroxy-4-thiophen-3-yloxybut-1-enyl]cyclopentyl]hept-5-enoic acid
CHEBI:180617
tiaprost
iliren
tiaprostum [inn-latin]
(+-)-(z)-7-((1r*,2r*,3r*,5s*)-3,5-dihydroxy-2-((e)-(3r*s*)-3-hydroxy-4-(3-thienyloxy)-1-butenyl)cyclopentyl)-5-heptenoic acid
(+-)-(z)-7-((1r*,2r*,3r*,5s)-3,5-dihydroxy-2-((e)-(3r*,s*)-3-hydroxy-4-(3-thienyloxy)-1-butenyl)cyclopentyl)-5-heptenoic acid
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-thienyloxy)-1-butenyl)cyclopentyl)-
iliren [veterinary] (tn)
tiaprost (inn)
71116-82-0
D08591
98e50hhh7m ,
tiaprostum
unii-98e50hhh7m
tiaprost [inn:ban]
CHEMBL2104879
tiaprost, (r,s)-
SCHEMBL867741
tiaprost [mart.]
tiaprost [inn]
tiaprost [mi]
(+/-)-(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((e)-(3rs)-3-hydroxy-4-(3-thienyloxy)but-1-enyl)cyclopentyl)hept-5-enoic acid
(5z,13e)-(9s,11r,15rs)-9,11,15-trihydroxy-16-(3-thienyloxy)-17,18,19,20-tetranorprosta-5,13-dienoic acid
Q27272116
WCA11682

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Tiaprost treatment reduced the interval from calving to conception in multiparous cows, but it delayed conception and reduced the conception rate in primiparous cows."( Endometritis treatment with a PGF2alpha analog does not improve reproductive performance in a large dairy herd in Argentina.
Lacau-Mengido, IM; Mejía, ME, 2005
)
1.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (33.33)18.7374
1990's2 (22.22)18.2507
2000's4 (44.44)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.29 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]